Prosecution Insights
Last updated: May 29, 2026

Examiner: SAEED, ALI S

Tech Center 1600 • Art Units: 1616

This examiner grants 30% of resolved cases

Performance Statistics

30.5%
Allow Rate
-29.5% vs TC avg
182
Total Applications
+34.8%
Interview Lift
1463
Avg Prosecution Days
Based on 118 resolved cases, 2023–2026

Rejection Statute Breakdown

0.3%
§101 Eligibility
1.7%
§102 Novelty
59.2%
§103 Obviousness
2.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
15766586 STABLE PROTEIN COMPOSITIONS Non-Final OA Regeneron Pharmaceuticals, Inc.
19258402 METHODS FOR MAKING L-GLUFOSINATE Final Rejection BASF SE
18265993 METHOD FOR OBTAINING CRYSTALLINE DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE Non-Final OA BASF SE
17261401 HERBICIDAL MIXTURES COMPRISING ISOXAFLUTOLE, SAFLUFENACIL AND AN IMIDAZOLINONE HERBICIDE; AND THEIR USE IN SOYBEAN AND COTTON CULTURES Final Rejection BASF SE
18652015 Monomethylfumarate Prodrug Compositions Non-Final OA Alkermes Pharma Ireland Limited
18292366 IMPROVED DRUG PROCESSING METHODS TO INCREASE DRUG LOADING Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17685512 ULTRASOUND MEDIATED POLYMERIZATION FOR CELL DELIVERY, DRUG DELIVERY AND 3D PRINTING Final Rejection Technion Research & Development Foundation Limited
17759694 METHOD FOR CONTROLLING QOI FUNGICIDE-RESISTANT SOYBEAN RUST FUNGI Non-Final OA SUMITOMO CHEMICAL COMPANY, LIMITED
18288289 INTRACELLULAR TARGETED NANOCARRIERS: TOWARDS CONTROLLED DRUG DELIVERY FOR NONINVASIVE NEUROREGENERATION TREATMENT Non-Final OA The Texas A&M University System
16423491 BEAD COMPOSITIONS FOR AQUATIC WEED CONTROL Final Rejection UPL LTD
18554163 MEDICAL DEVICE Non-Final OA SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD.
17770033 GROWTH ENHANCEMENT OF PLANT BY USING LOW MOLECULAR WEIGHT GUAR GUM Final Rejection RHODIA OPERATIONS
17298290 USE OF GUAR DERIVATIVES IN BIOFUNGICIDE COMPOSITIONS Non-Final OA RHODIA OPERATIONS
16894261 COATED POLYMERIC MATERIAL Final Rejection LifeCell Corporation
18591064 COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS Final Rejection Impact Biomedicines, Inc.
18294225 PLANT SURFACE PROTECTIVE COMPOSITION FOR DELAYING BUD-BREAK, METHODS OF USE AND MANUFACTURE Non-Final OA FROSTDEFENSE ENVIROTECH, INC.
17905924 COMPOSITIONS AND METHODS FOR EYE HEAL TH COMPRISING AREDS AND VITAMIN B COMPLEX Final Rejection BAUSCH + LOMB IRELAND LIMITED
18262216 METHOD FOR REALIZING CARTILAGE REGENERATION BY MEANS OF INOCULATING GEL CARTILAGE INTO FRAME STRUCTURE Non-Final OA SHANGHAI NINTH PEOPLE'S HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE
18208496 MACRONUTRIENT COMPOUNDS Non-Final OA Ralco Nutrition Inc.
17303863 ALKYL POLYGLYCERYLAMINE BASED SURFACTANTS FOR AGRICULTURAL USE Final Rejection NOURYON CHEMICALS INTERNATIONAL B.V.
18572637 NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS Non-Final OA LDN Pharma Limited
18571549 HAIR GROWTH AGENT Non-Final OA ADJUVANT HOLDINGS CO., LTD.
18512349 DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP AND TABLETS Final Rejection Productos Farmaceuticos, S.A. DE C.V.
18446153 METHODS AND COMPOSITIONS FOR ASSESSING AND TREATING EMETOGENIC DRUG-RELATED NAUSEA Non-Final OA Lankenau Institute for Medical Research
17460585 PHARMACEUTICAL COMPOSITION COMPRISING TIOTROPIUM BROMIDE MONOHYDRATE Final Rejection MEXICHEM FLUOR S.A. DE C.V.
16582710 PHARMACEUTICAL COMPOSITION Final Rejection MEXICHEM FLUOR S.A. DE C.V.
16582964 PHARMACEUTICAL COMPOSITION Final Rejection MEXICHEM FLUOR S.A. DE C.V.
16334156 PHARMACEUTICAL COMPOSITION Final Rejection MEXICHEM FLUOR S.A. DE C.V.
18190836 SCAFFOLD WOUND DRESSING Final Rejection SYLKE, INC.
17913578 MEDICAMENT FOR KILLING TUMOR CELLS Non-Final OA PhotoQ3 Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month